Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement